GTC
EWTX icon

Ghost Tree Capital’s Edgewise Therapeutics EWTX Stock Holding History

Ghost Tree Capital’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$5.2M Buy
+195,000
New +$3.88M 1.57% 25

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Ghost Tree Capital's EWTX Position: Q3 2024 in Review

Ghost Tree Capital opened a new position in Edgewise Therapeutics (EWTX) in Q3 2024: 195,000 shares worth $5.2M. The stake represents 1.57% of the portfolio and ranks #25 among its holdings.

177 funds tracked by Wall St. Rank hold EWTX as of Q3 2024.

  • Ghost Tree Capital held 195,000 shares of Edgewise Therapeutics worth $5.2M as of Q3 2024.
  • Edgewise Therapeutics was a new Ghost Tree Capital position in Q3 2024.
  • Edgewise Therapeutics made up 1.57% of Ghost Tree Capital's portfolio in Q3 2024, its #25 holding.
  • 177 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q3 2024.

Based on Ghost Tree Capital's 13F filing for Q3 2024, filed 14 Nov 2024.